These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26859833)

  • 1. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
    PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
    Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy.
    Gu J; Dong D; Long E; Tang S; Feng S; Li T; Wang L; Jiang X
    Int J Colorectal Dis; 2019 Dec; 34(12):2151-2159. PubMed ID: 31732877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy.
    Theile D; Grebhardt S; Haefeli WE; Weiss J
    Biochem Pharmacol; 2009 Dec; 78(11):1366-73. PubMed ID: 19622348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
    Robinson SM; Mann J; Manas DM; Mann DA; White SA
    HPB (Oxford); 2013 Aug; 15(8):581-7. PubMed ID: 23458185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
    Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
    Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.
    Kagawa Y; Wang C; Piao Y; Jin L; Tanizawa Y; Cai Z; Sunakawa Y
    Target Oncol; 2024 Jul; 19(4):575-585. PubMed ID: 38691296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines.
    Kitada N; Takara K; Minegaki T; Itoh C; Tsujimoto M; Sakaeda T; Yokoyama T
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):577-84. PubMed ID: 18030470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
    Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
    Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
    Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.